Geron Q3 net loss $41.1M; cash $195M; IMerge top-line results expected early Jan 2023

GERON CORP

2022-Q3 EPS reported -$0.26 revenue$493,000

Net loss of $41.1M ($0.10/share) vs $26.7M ($0.08/share) in Q3 2021; revenues $0.3M.
Cash and marketable securities $195M as of Sep 30, 2022; cash runway through mid-2024.
Top-line results from IMerge Phase 3 trial in lower risk MDS expected in early January 2023.
Class action lawsuit settlement for $24M (no admission of fault); court approval scheduled Q1 2023.
FY 2022 GAAP operating expense guidance reaffirmed at $155M-$165M; headcount 98 employees.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GERON CORP reported the three and nine months ended September 30, 2022 results: revenue $297,000 and $493,000, respectively, net income net loss of $41.1 million, or $0.10 per share, EPS $0.10 per share.

Period: the three and nine months ended September 30, 2022
Revenue: $297,000 and $493,000, respectively
Net income: net loss of $41.1 million, or $0.10 per share
EPS: $0.10 per share
Result: reported results

Exact text from the filing

For the third quarter of 2022, the Company reported a net loss of $41.1 million, or $0.10 per share, compared to $26.7 million, or $0.08 per share, for the comparable 2021 period. Net loss for the first nine months of 2022 was $99.3 million, or $0.26 per share, compared to $84.1 million, or $0.26 per share, for the comparable 2021 period. Revenues for the three and nine months ended September 30, 2022, were $297,000 and $493,000, respectively, compared to $109,000 and $353,000 for the comparable 2021 periods.

View on SEC.gov

Browse all earnings releases →

GERON CORP filing history →

Source: SEC EDGAR

accession 0000950170-22-021575

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.